AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

COYA · NASDAQ · Biotechnology

Coya Therapeutics

Develops Treg-focused therapies for neurodegenerative and immune-mediated diseases.

$4.57

After-hours close−0.02 (−0.52%)

At close$4.60(−5.45%)

Something off on this page? Send us feedback.

Profile

Coya Therapeutics, Inc.COYAHealth Care

Develops proprietary therapies intended to enhance regulatory T-cell function across neurodegenerative, inflammatory, autoimmune, and metabolic disease programs. Its development model includes licensed regional commercialization rights for COYA 302.

Develops proprietary therapies intended to enhance regulatory T-cell function, with programs spanning neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet need. COYA 302 is its named lead program, licensed to Dr. Reddy’s Laboratories for ALS commercialization across the United States, Canada, the European Union, and the United Kingdom.

Operates as a clinical-stage development organization rather than a commercial-product company. Development and regulatory progress, together with execution under the COYA 302 licensing arrangement, shape the business. It initially targets disorders with high unmet need across its current clinical programs.

Company facts

CEOArun Swaminathan, Ph.D.

ListedDec 29, 2022

ExchangeNASDAQ

HeadquartersHouston, TX

CountryUnited States

Employees8

CIK0001835022

ISINUS22407B1089

Key statistics

Market cap$107.7M

EPS (ttm)−$1.07

P/E (ttm)−4.29

ROE-0.2%

P/B0.0025

P/S13.43

Dividend yield—

Beta1.42vs XLV 0.64

Year to date −18.7% · Average volume (30d) 139.0K

Analysts

Price target, next 12 months$12.00+161.4%Median of 6 analysts · vs the Aug 28 close

ConsensusBuy6 of 6 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $4.59

High$12.00+161.4%

Median$12.00+161.4%

Low$12.00+161.4%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Target
Jun 5, 2026	Roth Capital	Target	$12
Nov 5, 2025	Lake Street	Target	$17

Earnings

EPS

Estimate−$0.35

ReportedDue Nov 11, 2026

Revenue

Estimate$110.0K

ReportedDue Nov 11, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 11, 2026Q2 FY26	−$0.35	−$0.28	+19.0%	$130.0K	$221.9K	+70.7%	+3.45%
May 12, 2026Q1 FY26	−$0.39	−$0.32	+17.9%	$150.0K	$300.0K	+100.0%	+5.83%
Mar 16, 2026Q4 FY25	−$0.27	−$0.34	−24.8%	$2.2M	$4.0M	+78.0%	−2.22%
Nov 12, 2025Q3 FY25	$0.02	−$0.10	−600.0%	$1.9M	$3.6M	+85.1%	−2.13%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$257.9K	$163.6K	$3.6M	$4.0M	$251.1K	$243.7K
Gross profit	−$5.0M	$156.8K	$3.6M	$4.0M	$251.1K	$243.7K
Operating income	−$7.7M	−$6.4M	−$1.9M	−$6.0M	−$7.6M	−$7.0M
Net income	−$7.3M	−$6.1M	−$2.1M	−$5.7M	−$7.2M	−$6.6M
Diluted EPS	−$0.44	−$0.36	−$0.13	−$0.34	−$0.32	−$0.28
Gross margin	-1,921.9%	95.8%	99.8%	100.0%	100.0%	100.0%
Operating margin	-2,976.9%	-3,920.5%	-53.8%	-152.3%	-3,042.1%	-2,891.1%

Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $6.0M · FY24 $3.6M · FY25 $7.9M

Balance sheet, Jun 30, 2026Cash & short-term investments $43.18B · Total debt $0 · Total assets $47.31B · Shareholders' equity $43.28B

Dividends

No dividends on record.

Ownership

Institutions 34.67%8.13M sharesInsiders 0.12%27.6K sharesOther 65.21%15.30M shares

Shares outstanding 23.46M · Float 20.01M · 85.3% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Dme Capital Management, LP	2.34M	9.96%	13F	May 15, 2026
Dr. Reddy's Laboratories, Inc.	2.27M	9.70%	13G	Mar 12, 2026
Orin Hirschman	1.11M	5.30%	13G	Jan 28, 2026
Aigh Capital Management LLC	975.4K	4.16%	13F	Apr 30, 2026
Vanguard Capital Management LLC	844.9K	3.60%	13F	May 15, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.